Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 15,000 shares at $146.89 ($2.2M) on 2012-09-19, disclosed to the SEC on 2012-09-20.
Scheduled sale ($2.2M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $148.78 | 1,693 | $252K | 11.3% |
| 2 | $148.78 | 6,130 | $912K | 41.1% |
| 3 | $146.89 | 2,977 | $437K | 19.7% |
| 4 | $147.16 | 3,200 | $471K | 21.2% |
| 5 | $148.00 | 1,000 | $148K | 6.7% |
| Total | $148.01 avg | 15,000 |
| $2.2M |
| 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |